Harvard Bioscience, Inc. (HBIO) News
Follow Harvard Bioscience, Inc. (HBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Harvard Bioscience Reports Third-Quarter 2026 Results, Reaffirms Guidance
Harvard Bioscience reported third-quarter 2026 revenue of $22.2 million, versus $20.6 million a year earlier, and gross margin of 55.4%. Nine-month revenue was $65.7 million, compared with $62.8 million. The company reaf
EQUITY | Nov 10, 2026, 02:04 PM UTC
M
Harvard Bioscience Q3 Results Expected November 10
Harvard Bioscience is set to report Q3'26 results before market open on November 10. Revenue is estimated at $21.80 million and EPS at $(0.33).
EQUITY | Nov 09, 2026, 12:02 PM UTC
L
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
Harvard Bioscience (NASDAQ: HBIO ) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.
EARNINGS | Aug 11, 2026, 11:05 AM UTC